{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:46:38Z","timestamp":1782841598306,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA289447"],"award-info":[{"award-number":["R01 CA289447"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K22 AI146141"],"award-info":[{"award-number":["K22 AI146141"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejps.2024.106974","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T22:55:11Z","timestamp":1732661711000},"page":"106974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-5506","authenticated-orcid":false,"given":"Scott G.","family":"Tilden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison H.","family":"Ricco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Hemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Anchordoquy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106974_bib0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Controll. Release"},{"key":"10.1016\/j.ejps.2024.106974_bib0039","doi-asserted-by":"crossref","first-page":"e81370","DOI":"10.7554\/eLife.81370","article-title":"Transcriptional drifts associated with environmental changes in endothelial cells","volume":"12","author":"Afshar","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.ejps.2024.106974_bib0032","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejps.2024.106974_bib0043","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1128\/JVI.03129-14","article-title":"Control of hepatitis C virus replication in mouse liver-derived cells by MAVS-dependent production of type I and type III interferons","volume":"89","author":"Anggakusuma","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.ejps.2024.106974_bib0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1021\/mp500604r","article-title":"Relating toxicity to transfection: using sphingosine to maintain prolonged expression in vitro","volume":"12","author":"Betker","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2024.106974_bib0036","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4155\/tde.15.77","article-title":"Effect of charge ratio on lipoplex-mediated gene delivery and liver toxicity","volume":"6","author":"Betker","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejps.2024.106974_bib0031","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.xphs.2021.12.017","article-title":"The effect of repeat administration of lipoplexes on gene delivery, biodistribution, and cytokine response in immunocompetent tumor-bearing mice","volume":"111","author":"Betker","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106974_bib0052","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1084\/jem.20140995","article-title":"IFN-\u03bb resolves inflammation via suppression of neutrophil infiltration and IL-1\u03b2 production","volume":"212","author":"Blazek","year":"2015","journal-title":"J. Experim. Med."},{"key":"10.1016\/j.ejps.2024.106974_bib0016","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190295","article-title":"Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion","volume":"217","author":"Broggi","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejps.2024.106974_bib0028","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1016\/j.biomaterials.2012.04.019","article-title":"The use of CpG-free plasmids to mediate persistent gene expression following repeated aerosol delivery of pDNA\/PEI complexes","volume":"33","author":"Davies","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2024.106974_bib0047","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1189\/jlb.0812395","article-title":"Interferon-lambda (IFN-\u03bb) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes","volume":"93","author":"Dickensheets","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejps.2024.106974_bib0055","unstructured":"DOXORUBICIN (doxorubicin hydrochloride) | Pfizer Medical Information - US. https:\/\/www.pfizermedicalinformation.com\/en-us\/doxorubicin."},{"key":"10.1016\/j.ejps.2024.106974_bib0046","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.21312","article-title":"Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes","volume":"44","author":"Doyle","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ejps.2024.106974_bib0037","series-title":"Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes","volume":"7","author":"Gabizon","year":"1992"},{"key":"10.1016\/j.ejps.2024.106974_bib0053","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2017.04.025","article-title":"Interferon-\u03bb mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness","volume":"46","author":"Galani","year":"2017","journal-title":"Immunity."},{"key":"10.1016\/j.ejps.2024.106974_bib0014","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.immuni.2020.07.024","article-title":"Interferon-\u03bb at the center of the storm","volume":"53","author":"Hendricks","year":"2020","journal-title":"Immunity."},{"key":"10.1016\/j.ejps.2024.106974_bib0041","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1159\/000360084","article-title":"Interferon-\u03bb in the context of viral infections: production, response and therapeutic implications","volume":"6","author":"Hermant","year":"2014","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.ejps.2024.106974_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087906","article-title":"Human but not mouse hepatocytes respond to interferon-lambda in vivo","volume":"9","author":"Hermant","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.ejps.2024.106974_bib0042","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coi.2005.11.008","article-title":"The mononuclear phagocyte system","volume":"18","author":"Hume","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejps.2024.106974_bib0027","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt1399","article-title":"CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression","volume":"26","author":"Hyde","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejps.2024.106974_bib0048","article-title":"Interferon-\u03bb receptor expression: novel reporter mouse reveals within- and cross-tissue heterogeneity","author":"J","year":"2020","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejps.2024.106974_bib0020","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.33354","article-title":"IFN-\u03bb prevents influenza virus spread from the upper airways to the lungs and limits virus transmission","volume":"7","author":"Klinkhammer","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.ejps.2024.106974_bib0019","doi-asserted-by":"crossref","first-page":"284ra59","DOI":"10.1126\/scitranslmed.aaa4304","article-title":"Interferon-\u03bb restricts West Nile virus neuroinvasion by tightening the blood-brain barrier","volume":"7","author":"Lazear","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejps.2024.106974_bib0015","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity."},{"key":"10.1016\/j.ejps.2024.106974_bib0029","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.gt.3300482","article-title":"In vivo gene transfer via intravenous administration of cationic lipid\u2013protamine\u2013DNA (LPD) complexes","volume":"4","author":"Li","year":"1997","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejps.2024.106974_bib0030","doi-asserted-by":"crossref","first-page":"L796","DOI":"10.1152\/ajplung.1999.276.5.L796","article-title":"Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors","volume":"276","author":"Li","year":"1999","journal-title":"Am. J. Physiol.-Lung Cellular Mol. Physiol."},{"key":"10.1016\/j.ejps.2024.106974_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/v12040405","article-title":"Interferon-\u03bb attenuates rabies virus infection by inducing interferon-stimulated genes and alleviating neurological inflammation","volume":"12","author":"Li","year":"2020","journal-title":"Viruses."},{"key":"10.1016\/j.ejps.2024.106974_bib0056","article-title":"Distinct roles of type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infections","volume":"12","author":"Lin","year":"2016","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.ejps.2024.106974_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2015.04.024","article-title":"Efficient in vivo transfection and safety profile of a CpG-free and codon optimized luciferase plasmid using a cationic lipophosphoramidate in a multiple intravenous administration procedure","volume":"59","author":"Lindberg","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2024.106974_bib0038","doi-asserted-by":"crossref","first-page":"e88248","DOI":"10.7554\/eLife.88248","article-title":"How their environment influences endothelial cells","volume":"12","author":"Liu","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.ejps.2024.106974_bib0034","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol\u2013coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ejps.2024.106974_bib0012","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/pathogens9120989","article-title":"The key roles of interferon lambda in human molecular defense against respiratory viral infections","volume":"9","author":"Lozhkov","year":"2020","journal-title":"Pathogens."},{"key":"10.1016\/j.ejps.2024.106974_bib0033","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejps.2024.106974_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004782","article-title":"Leukocyte-derived IFN-\u03b1\/\u03b2 and epithelial IFN-\u03bb constitute a compartmentalized mucosal defense system that restricts enteric virus infections","volume":"11","author":"Mahlak\u00f5iv","year":"2015","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.ejps.2024.106974_bib0006","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.ejps.2024.106974_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000151","article-title":"Interferon-\u03bb contributes to innate immunity of mice against influenza a virus but not against hepatotropic viruses","volume":"4","author":"Mordstein","year":"2008","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.ejps.2024.106974_bib0017","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1128\/JVI.00272-10","article-title":"Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections","volume":"84","author":"Mordstein","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.ejps.2024.106974_bib0044","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.23743","article-title":"Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection","volume":"52","author":"Muir","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejps.2024.106974_bib0045","doi-asserted-by":"crossref","first-page":"e59611","DOI":"10.1371\/journal.pone.0059611","article-title":"Targeted induction of interferon-\u03bb in humanized chimeric mouse liver abrogates hepatotropic virus infection","volume":"8","author":"Nakagawa","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.ejps.2024.106974_bib0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coviro.2015.02.003","article-title":"The unique regulation and functions of type III interferons in antiviral immunity","volume":"12","author":"Odendall","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejps.2024.106974_bib0018","doi-asserted-by":"crossref","first-page":"7944","DOI":"10.1073\/pnas.1100552108","article-title":"IFN-\u03bb determines the intestinal epithelial antiviral host defense","volume":"108","author":"Pott","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.ejps.2024.106974_bib0023","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa2209760","article-title":"Early treatment with pegylated interferon lambda for Covid-19","volume":"388","author":"Reis","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2024.106974_bib0008","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/jpet.104.078113","article-title":"Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid","volume":"312","author":"Semple","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2024.106974_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106974_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-\u03bb) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.ejps.2024.106974_bib0026","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1089\/hum.1997.8.13-1585","article-title":"Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration","volume":"8","author":"Song","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejps.2024.106974_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1573403X10666140914160554","article-title":"Nanoparticles and the mononuclear phagocyte system: pharmacokinetics and applications for inflammatory diseases","volume":"10","author":"Song","year":"2014","journal-title":"Curr. Rheumatol. Rev."},{"key":"10.1016\/j.ejps.2024.106974_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107863","article-title":"Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells","author":"Stanifer","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejps.2024.106974_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02540-20","article-title":"The TLR3\/IRF1\/Type III IFN axis facilitates antiviral responses against enterovirus infections in the intestine","volume":"11","author":"Su","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.ejps.2024.106974_bib0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2024.106974_bib0007","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3390\/nano11061528","article-title":"Cross-species comparisons of nanoparticle interactions with innate immune systems: a methodological review","volume":"11","author":"Swartzwelter","year":"2021","journal-title":"Nanomaterials. (Basel)"},{"key":"10.1016\/j.ejps.2024.106974_bib0009","doi-asserted-by":"crossref","first-page":"13015","DOI":"10.1021\/acsnano.9b05679","article-title":"Overcoming the reticuloendothelial system barrier to drug delivery with a \u201cDon't-eat-us\u201d strategy","volume":"13","author":"Tang","year":"2019","journal-title":"ACS. Nano"},{"key":"10.1016\/j.ejps.2024.106974_bib0003","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jconrel.2023.05.029","article-title":"Reducing off-target drug accumulation by exploiting a type-III interferon response","volume":"358","author":"Tilden","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2024.106974_bib0024","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/sj.gt.3302050","article-title":"A comparison of linear and branched polyethylenimine (PEI) with DCChol\/DOPE liposomes for gene delivery to epithelial cells in vitro and in vivo","volume":"10","author":"Wiseman","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejps.2024.106974_bib0004","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2019.05.030","article-title":"Liposome and immune system interplay: Challenges and potentials","volume":"305","author":"Zahednezhad","year":"2019","journal-title":"J. Controll. Release"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724002872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724002872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:38:06Z","timestamp":1738438686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724002872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":55,"alternative-id":["S0928098724002872"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106974","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106974"}}